Program
Ibuprofen
Also written as “ibuprofen”, “Intravenous ibuprofen” and “Ibuprofen/acetaminophen”.
Its studies are mostly in Pain · Pain, Postoperative · Osteoarthritis · Fever · Osteoarthritis, Knee, led by 36 companies.
Drug pageIbuprofen: every studyMany companies study it; this page follows only the 101 they lead. All 433 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 150 open or running | phase 4since Aug 22, 2008 | Aug 22, 2008 | none ahead |
| Cumberland Pharmaceuticalsits history only | 90 open or running | phase 4since Apr 12, 2011 | Sep 22, 2005 | none ahead |
| Johnson & Johnsonits history only | 70 open or running | phase 4since Oct 14, 2005 | Oct 14, 2005 | none ahead |
| Boehringer Ingelheimits history only | 60 open or running | phase 3since Aug 22, 2013 | Jul 26, 2010 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 60 open or running | phase 1since Jan 20, 2010 | Jan 20, 2010 | none ahead |
| Reckittits history only | 60 open or running | phase 3since Oct 26, 2010 | Oct 26, 2010 | none ahead |
| AFT Pharmaceuticalsits history only | 51 open or running | phase 3since Aug 16, 2011 | Apr 14, 2010 | Mar 2027phase 3 · NCT07225634 |
| Strategic Science & Technologiesits history only | 40 open or running | phase 3since Oct 11, 2012 | Oct 11, 2012 | none ahead |
| Angelini Pharmaits history only | 30 open or running | phase 1since Jun 17, 2015 | Jun 17, 2015 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 4since Mar 28, 2013 | Sep 5, 2006 | none ahead |
| Hypera Pharmaits history only | 30 open or running | phase 4since May 20, 2011 | Jul 28, 2010 | none ahead |
| Pierre Fabreits history only | 30 open or running | phase 3since Feb 5, 2013 | Feb 10, 2012 | none ahead |
| Amgenits history only | 20 open or running | phase 4since Mar 20, 2012 | Mar 19, 2007 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 20 open or running | phase 3since Jul 18, 2024 | Jun 15, 2022 | none ahead |
| medherant-ltdits history only | 20 open or running | phase 1since Aug 16, 2018 | Aug 16, 2018 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 20 open or running | phase 3since Mar 22, 2012 | Mar 22, 2012 | none ahead |
| overseas-pharmaceuticals-ltdits history only | 21 open or running | phase 3since Dec 20, 2021 | Feb 4, 2021 | none ahead |
| oxford-pharmascience-ltdits history only | 20 open or running | phase 1since Aug 5, 2015 | Aug 5, 2015 | none ahead |
| perrigo-companyits history only | 20 open or running | phase 1since Dec 5, 2008 | Dec 5, 2008 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Mar 8, 2016 | Mar 8, 2016 | none ahead |
| biochemics-incits history only | 10 open or running | phase 2since Dec 15, 2011 | Dec 15, 2011 | none ahead |
| biomendi-s-a-uits history only | 10 open or running | phase 3since Sep 25, 2014 | Sep 25, 2014 | none ahead |
| futura-medical-developments-ltdits history only | 10 open or running | phase 1since Jan 20, 2016 | Jan 20, 2016 | none ahead |
| future-sciene-technologyits history only | 10 open or running | phase 4since Dec 11, 2014 | Dec 11, 2014 | none ahead |
| HALEONits history only | 10 open or running | phase 1since Dec 12, 2025 | Dec 12, 2025 | none ahead |
| Hamad Medicalits history only | 10 open or running | early phase 1since Oct 7, 2019 | Oct 7, 2019 | none ahead |
| laborato-rio-teuto-brasileiro-s-aits history only | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| lahore-medical-research-center-llpits history only | 10 open or running | phase 3since Feb 23, 2024 | Feb 23, 2024 | none ahead |
| Menarini Groupits history only | 10 open or running | phase 1since Jun 17, 2025 | Jun 17, 2025 | none ahead |
| Merckits history only | 10 open or running | phase 1since Nov 28, 2007 | Nov 28, 2007 | none ahead |
| qc-kinetix-llcits history only | 10 open or running | phase 2since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Aug 31, 2011 | Aug 31, 2011 | none ahead |
| scolr-pharma-incits history only | 10 open or running | phase 3since Jun 26, 2008 | Jun 26, 2008 | none ahead |
| simbec-researchits history only | 10 open or running | phase 1since Sep 16, 2014 | Sep 16, 2014 | none ahead |
| spherium-biomedits history only | 10 open or running | phase 2since Nov 10, 2015 | Nov 10, 2015 | none ahead |
| x-pert-med-gmbhits history only | 10 open or running | phase 1since Jan 22, 2010 | Jan 22, 2010 | none ahead |
Also a collaborator on its studies: Premier Research Group, Parexel, Aptuit, Cross Research, Pharma Consulting Group AB, Pivotal S.L. and AAIPharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 3, 2011.
- Oct 25, 2018Phase 3 study in PainPfizer · NCT03722238 · 613 enrolled · United States
- Dec 17, 2018Phase 3 study in PainReckitt · NCT03785756 · 280 enrolled · United States
- Oct 7, 2019Hamad Medical’s first study: early phase 1 study in FeverNew to Hamad MedicalHamad Medical · NCT04123717 · 147 enrolled · Qatar
- Feb 4, 2021overseas-pharmaceuticals-ltd’s first study: phase 1 study in Chronic PainNew to overseas-pharmaceuticals-ltdoverseas-pharmaceuticals-ltd · NCT05329454 · 30 enrolled · China
- Aug 3, 2021Phase 3 study in Musculoskeletal PainHypera Pharma · NCT05013567 · 300 enrolled
- Dec 20, 2021Phase 3 study in Osteoarthritisoverseas-pharmaceuticals-ltd · NCT05318521 · 500 enrolled · United States, Taiwan
- Jun 15, 2022Laboratorios Silanes S.A. de C.V.’s first study: phase 1 study in PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT05428306 · 42 enrolled · Mexico
- Jul 27, 2022Phase 3 study in Tooth, ImpactedReckitt · NCT05484401 · 294 enrolled · United States
- Feb 6, 2023qc-kinetix-llc’s first study: phase 2 study in Osteoarthritis, KneeNew to qc-kinetix-llcqc-kinetix-llc · NCT05742763 · United States
- Feb 23, 2024lahore-medical-research-center-llp’s first study: phase 3 study in Primary DysmenorrheaNew to lahore-medical-research-center-llplahore-medical-research-center-llp · NCT06317064 · 40 enrolled · Pakistan
- Jul 18, 2024Phase 3 study in Common ColdLaboratorios Silanes S.A. de C.V. · NCT06531707 · 177 enrolled · Mexico
- Jun 17, 2025Menarini Group’s first study: phase 1 study in Healthy Male and Female SubjectsNew to Menarini GroupMenarini Group · NCT07036861 · 74 enrolled · Lithuania
- Oct 30, 2025Phase 3 study in Acute PainAFT Pharmaceuticals · NCT07225634 · 60 planned · Hungary
- Dec 12, 2025HALEON’s first study: phase 1 study in BioequivalenceNew to HALEONHALEON · NCT07345130 · 68 enrolled · United States
Ahead
- Mar 2027Primary completion: phase 3 study in Acute PainAFT Pharmaceuticals · NCT07225634
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
The newest 60 of 101 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07345130Bioequivalence · United States | 1 | Completed | HALEON | Feb 3, 2026 | 68 |
| NCT07225634Acute Pain · Hungary | 3 | Recruiting | AFT Pharmaceuticals | Mar 2027 | 60 |
| NCT07036861Healthy Male and Female Subjects · Lithuania | 1 | Completed | Menarini Group | Apr 8, 2024 | 74 |
| NCT06531707Common Cold · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Jan 20, 2025 | 177 |
| NCT06317064Primary Dysmenorrhea · Pakistan | 3 | Completed | lahore-medical-research-center-llp | Oct 31, 2024 | 40 |
| NCT05742763Osteoarthritis, Knee · United States | 2 | Withdrawn | qc-kinetix-llc | Oct 7, 2024 | 0 |
| NCT05484401Tooth, Impacted · United States | 3 | Completed | Reckitt | Jun 15, 2023 | 294 |
| NCT05428306Pain · Mexico | 1 | Completed | Laboratorios Silanes S.A. de C.V. | Nov 6, 2018 | 42 |
| NCT05318521Osteoarthritis · United States, Taiwan | 3 | Active, not recruiting | overseas-pharmaceuticals-ltd | Aug 12, 2022 | 500 |
| NCT05013567Musculoskeletal Pain | 3 | UNKNOWN | Hypera Pharma | May 2023 | 300 |
| NCT05329454Chronic Pain · China | 1 | Completed | overseas-pharmaceuticals-ltd | Feb 6, 2021 | 30 |
| NCT04123717Fever · Qatar | Early 1 | Completed | Hamad Medical | Mar 7, 2024 | 147 |
| NCT03785756Pain · United States | 3 | Completed | Reckitt | Feb 20, 2020 | 280 |
| NCT03722238Pain · United States | 3 | Terminated | Pfizer | Oct 28, 2019 | 613 |
| NCT03694587Healthy · Bulgaria | 1 | Completed | medherant-ltd | Oct 18, 2018 | 16 |
| NCT03639571Healthy · Bulgaria | 1 | Completed | medherant-ltd | Oct 25, 2018 | 33 |
| NCT03658720Healthy · United Kingdom | – | Terminated | Reckitt | Dec 21, 2017 | 29 |
| NCT03496324Bioequivalence of the Test Formulation | 1 | Completed | Reckitt | May 6, 2016 | 24 |
| NCT03497715Healthy Subjects | 1 | Terminated | Reckitt | Jul 30, 2015 | 6 |
| NCT02974361Pharmacokinetics · United Kingdom | 1 | Completed | oxford-pharmascience-ltd | Apr 28, 2017 | 30 |
| NCT03003000Back Pain · Germany, Russian Federation | 3 | Completed | Boehringer Ingelheim | Sep 24, 2017 | 635 |
| NCT02963701Healthy Volunteers · South Africa | 1 | Completed | Boehringer Ingelheim | Jan 31, 2017 | 56 |
| NCT02902302Healthy · Switzerland | 1 | Completed | Angelini Pharma | Jun 2016 | 60 |
| NCT02902289Healthy · Switzerland | 1 | Completed | Angelini Pharma | Jul 2016 | 60 |
| NCT02863575Pain · United States | 3 | Completed | Pfizer | Apr 6, 2018 | 374 |
| NCT02761980Fever · United States | 3 | Completed | Pfizer | Dec 6, 2017 | 290 |
| NCT02904304Common Cold · Brazil | 3 | Suspended | Ache Laboratorios Farmaceuticos | Jul 2021 | 150 |
| NCT02689063Pain, Postoperative · United States | 3 | Completed | AFT Pharmaceuticals | Jun 30, 2017 | 276 |
| NCT02666846Pain · United Kingdom | 1 | Completed | futura-medical-developments-ltd | May 2015 | 60 |
| NCT02912650Pain · United States | 3 | Completed | Pfizer | Jun 2016 | 568 |
| NCT02602483Temporomandibular Joint Disorders · Spain | 2 | Completed | spherium-biomed | Dec 2016 | 96 |
| NCT02583399Pain · United States | 4 | Completed | Cumberland Pharmaceuticals | Jul 2, 2019 | 30 |
| NCT02597634Delayed Onset Muscle Soreness, DOMS · United States | 3 | Completed | Strategic Science & Technologies | Oct 2016 | 156 |
| NCT02521207Gastroduodenal Erosions · United Kingdom | 1 | Completed | oxford-pharmascience-ltd | Aug 2015 | 53 |
| NCT02482155Healthy · Switzerland | 1 | Completed | Angelini Pharma | Mar 2015 | 24 |
| NCT02339129Delayed Onset Muscle Soreness · United States | 2 | Completed | Strategic Science & Technologies | Feb 2015 | 72 |
| NCT02327338Pain · United States | 4 | Completed | future-sciene-technology | Feb 2015 | 90 |
| NCT02294019Patient Compliance · United States | 3 | Completed | Pfizer | May 2015 | 738 |
| NCT02254525Pain, Postoperative · Spain | 3 | Terminated | biomendi-s-a-u | Jun 2014 | 231 |
| NCT02256423Healthy Volunteer Study · United Kingdom | 1 | Completed | simbec-research | Aug 2014 | 24 |
| NCT02183051Pain | 2 | Completed | Boehringer Ingelheim | Oct 1998 | 381 |
| NCT01986660Healthy · United States | 1 | Completed | Strategic Science & Technologies | Oct 2013 | 14 |
| NCT01929031Pain, Postoperative · United States | 3 | Completed | Boehringer Ingelheim | Mar 2014 | 562 |
| NCT01901393Pain · United States | 4 | Completed | Cumberland Pharmaceuticals | Aug 2014 | 100 |
| NCT01879371Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2013 | 36 |
| NCT01859377Healthy Volunteers · Belgium | 1 | Completed | Pierre Fabre | Jun 2013 | 26 |
| NCT01822665Gastrointestinal Mucosal Damage · United States | 4 | Completed | GlaxoSmithKline | Jul 2012 | 28 |
| NCT01785862Respiratory Tract Infections · France, Germany, Latvia and more | 3 | Completed | Pierre Fabre | Jun 2013 | 427 |
| NCT01771822Pain · United States | 1 | Completed | Pfizer | Feb 2013 | 50 |
| NCT01874626Lymphoma, Follicular · United States | 3 | Completed | Strategic Science & Technologies | Jan 2014 | 305 |
| NCT01789606Agnosia · United States | 3 | Completed | Pfizer | Jun 3, 2013 | 1,083 |
| NCT01650519Arthroscopic Knee Surgery · United States | 4 | Completed | Cumberland Pharmaceuticals | Dec 2012 | 51 |
| NCT01563289Pain · Finland | 3 | Completed | Orion Corporation, Orion Pharma | Jul 2012 | 62 |
| NCT01562717Pain · Finland | 3 | Completed | Orion Corporation, Orion Pharma | Oct 2012 | 62 |
| NCT01563185Arthritis, Juvenile · United States | 4 | Completed | Amgen | Mar 2015 | 12 |
| NCT01559259Pain · United States | 2 | Completed | Pfizer | Sep 13, 2012 | 394 |
| NCT01555476Pain · Sweden | 1 | Completed | Johnson & Johnson | Mar 2012 | 32 |
| NCT01535079Respiratory Tract Infections · France, Germany, United Kingdom | 2 | Completed | Pierre Fabre | Nov 2012 | 186 |
| NCT01496326Osteoarthritis · Switzerland | 2 | Completed | biochemics-inc | Aug 2011 | 75 |
| NCT01466517Healthy · Brazil | 4 | Completed | Pfizer | Nov 2011 | 70 |
How it is read
Names in the registry
- “Ibuprofen”, 40 entries
- “ibuprofen”, 10 entries
- “Intravenous ibuprofen”, 5 entries
- “Ibuprofen/acetaminophen”, 4 entries
- “ibuprofen + caffeine”, 3 entries
Codes read as this program: SST0225.
Conditions, from the studies’ own filings
- Pain, 28 studies
- Pain, Postoperative, 6 studies
- Osteoarthritis, 5 studies
- Fever, 5 studies
- Osteoarthritis, Knee, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.